| CLEU | China Liberal Education Holdings | 24.04.2020 | Invest in IPO |
| NRI | Fortis Minerals | Expected | Invest in IPO |
| CNTX | Centrexion Therapeutics Corp | Expected | Invest in IPO |
| DDDD | 4D Molecular Therapeutics | Expected | Invest in IPO |
| CMDS | CloudMinds | Expected | Invest in IPO |
Educational service provider operating under the “China Liberal” brand in the PRC. Our mission is to provide China’s students with the tools to excel in a global environment. We strive to meet the needs of the ever growing number of young talents in China.
We are a returns-focused company formed to pursue oil and natural gas mineral and royalty interest opportunities in leading oil-weighted onshore domestic resource plays.
We are a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain.
We are a development stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors.
We have built and operate an open end-to-end cloud robot system, and offer it as a service to the world.
FOLLOW-ON OFFERING: Nasdaq uplisting; VerifyMe, Inc. (“VerifyMe,” the “Company,” “we” or “us”) is a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products.
We are a pioneer and leader in China’s used car financing market, focusing on facilitating loans from financial institutions to prime borrowers in used car transactions.
We are a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
We operate the largest co-working space community in China in terms of the number of co-working spaces, aggregate managed area and number of cities covered in China as of September 30, 2019, according to Frost & Sullivan.
We are a high-growth, healthcare and wellness company that sells topical products to improve immune health, neuromuscular health and skin barrier health.
We offer augmented reality ("AR")-based holographic services and products to cater to our customers' needs, all centered upon providing an innovative, immersive and interactive holographic augmented reality experience for our customers and end users. Currently, our offerings consist primarily of (i) holographic AR advertising services and (ii) holographic AR entertainment products.
We are a biotechnology company that is focused on the discovery and development of novel molecules and related diagnostics to treat high unmet medical needs in oncology and immunology.
We are a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System ("CNS") disorders and other rare disorders.
We are a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options.
We are a provider of healthcare information, education, and training services to healthcare professionals and the public in China.
AESE operates a premier public esports and entertainment company, consisting of the Allied Esports and World Poker Tour businesses.
Uplisting, Follow-on Offering: Unit offering containing one common and one warrant, the common stock and warrants will be issued separately and will be immediately separable upon issuance.
Muscle Maker is a fast casual restaurant concept that specializes in preparing healthy-inspired, high-quality, fresh, made-to-order lean, protein-based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads.
FOLLOW-ON/Uplisting offering
UP-LISTING/FOLLOW-ON OFFERING: We have designed and developed, and now own and operate, a business-to-business, web-based marketplace focused on the United States pharmaceutical industry. Our core service brings the nation’s independent pharmacies and accredited national suppliers of pharmaceuticals together to provide efficient and transparent buying and selling opportunities.
© 2020 Just2Trade Online Ltd
Just2Trade Online Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015.
Registration Number:: HE 341520
Address: Just2Trade Online Ltd
10 Chrysanthou Mylona, MAGNUM HOUSE
3030 Limassol, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
www.finam.eu and www.finam.com.cy are owned by Just2Trade Online Ltd.
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in full risk disclosure.
Investment risks related to other instruments can be found in the following disclosure.
E-mail: 24_support@just2trade.online
